Figure 4
Figure 4. Correlation between serum CRP at baseline and serum IL-6 at baseline or after tocilizumab administration. ■ and ● show patients with RA and patients with Castleman disease, respectively. The x-axis shows (A) serum IL-6 at baseline (r2 = .19) and (B) serum IL-6 after tocilizumab infusion (r2 = .67).

Correlation between serum CRP at baseline and serum IL-6 at baseline or after tocilizumab administration. ■ and ● show patients with RA and patients with Castleman disease, respectively. The x-axis shows (A) serum IL-6 at baseline (r2 = .19) and (B) serum IL-6 after tocilizumab infusion (r2 = .67).

Close Modal

or Create an Account

Close Modal
Close Modal